A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Cancer Clinical Trial

— BETA-PRIME  

Official title:

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04673942
• Other study ID #: BETA-PRIME
• Status: Recruiting
• Phase: Phase 2
• Start date: March 29, 2021
• Est. completion date: March 1, 2027

Study information

• Verified date: May 2024
• Source: EpicentRx, Inc.
• Contact: Jeannie Williams
• Phone: 858-947-6644
• Email: jwilliams[@]epicentrx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.

Description:

This is a dose escalation protocol to determine, first and foremost, the safety, tolerability and feasibility of intratumoral administration of AdAPT-001.

The study has 3 parts. Different groups of patients will participate in each part.

PHASE 1 PART 1: Dose Escalation Safety Run-In (CLOSED - Enrollment Completed) During PART 1, all participants will be treated with AdAPT-001 as a single injection, one time. Participants will be assigned to different dose levels to find the highest dose of AdAPT-001 that is safe and tolerable.

PHASE 1 PART 2: Dose Expansion Single-Agent (CLOSED - Enrollment Completed) All participants in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.

PHASE 1 PART 3: Expansion (CLOSED - Enrollment Completed) Subjects will be assigned to the following two arms. If a checkpoint inhibitor is indicated for the subject, the subject may be enrolled on Arm 2 per investigator discretion, otherwise subjects may be enrolled on Arm 1.

Arm 1: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections.

Arm 2: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections plus a checkpoint inhibitor per investigator discretion

PHASE 2: (OPEN to Enrollment)

Subjects with advanced solid tumors will participate in a basket two-arm parallel group evaluation (Phase 2) where eligible participants will be assigned to the following two arms based on confirmed histology by the treating investigator.

Arm 1: Confirmed Histological Diagnosis of Sarcoma Intratumoral Administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections with or without a checkpoint inhibitor.

Arm 2: Confirmed Histological Diagnosis of Advanced Solid Tumor indicated to receive at least one checkpoint inhibitor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: March 1, 2027
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is capable of understanding the purpose and risks of the study and has provided written Informed Consent.

2. Subject is male or female, aged at least 18 years.

3. Subject has a histologically or cytologically confirmed diagnosis of an advanced malignant solid tumor(s) who have received all conventional therapies considered appropriate by Investigator and have a tumor that is easily accessible and/or palpable for treatment. Ultrasound guidance may be used to aid administration.

4. Subject's Eastern Cooperative Group (ECOG) performance status is 0-1 at Screening.

5. Subject has acceptable liver function at Screening, as evidenced by:

1. Bilirubin < 1.5 x ULN (upper limit of normal)

2. AST (SGOT) and ALT (SGPT) < 3.0 x ULN (upper limit of normal)

3. Alkaline Phosphatase < 2.5 x ULN (upper limit of normal)

6. Subject has a Serum Creatinine < 1.5 x ULN (upper limit of normal)

7. Subject has acceptable hematologic status at Screening, as evidenced by:

1. Absolute neutrophil count > 1,500 cells/mm3; > 1.5 x 109/L, and

2. Platelet count > 75,000/mm3; > 75.0 x 109/L, and

3. Hemoglobin (HGB) = 8.0 g/dL; = 5.6 mmol/L

8. Subject has an INR < 1.5

9. Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of AdAPT-001. Medically acceptable contraception is defined as either: 1) usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Study Day 1, of a stable regimen of any form of hormonal contraception or an intra-uterine device, or 2) usage by the couple of a double-barrier method of contraception. Use of a single-barrier method alone or abstinence alone is not considered adequate.

10. Subject is willing and able to comply with all protocol procedures, evaluations and rescue measures.

11. OPTIONAL: Archival formalin-fixed paraffin-embedded block(s) or previously cut archival tissue for at least 5 unstained slides (if available).

Exclusion Criteria:

1. Presence of a serious co-morbid medical condition, or a clinically significant laboratory finding(s) that, in the opinion of the Investigator, suggests the presence of an infectious, endocrine, and/or other inadequately treated systemic disorder.

2. A known uncontrolled active bacterial, fungal, or viral infection. No subject with an active SARS-CoV-2 infection (within 14 days of a positive test)

3. Known positive history of human immunodeficiency virus (HIV) test

4. Subjects who have active hepatitis.

5. If female, subject is pregnant and/or breastfeeding.

6. Subjects with active autoimmune disease or history of autoimmune disease that might recur and may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded.

Note: Subjects in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days before AdAPT-001), but currently or previously treated with any of the following steroid regimens were included: Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; prophylactic short-term use of corticosteroids.

7. Prior adenoviral therapy for any indication except vaccination against infectious disease. Subjects receiving COVID-19 or live vaccination, cannot start treatment until 7 days after completing the vaccination. Recommend waiting at least 28 days from AdAPT-001 dose prior to receiving COVID-19 vaccination. Concurrent treatment with Evusheld is allowed.

8. Chemotherapy or immunotherapy within 14 days of study treatment. Hormonal therapy (including tamoxifen, aromatase inhibitors, and gonadotropin releasing hormone agonists) is allowed. Concurrent treatment with bisphosphonate and RANK ligand inhibitor is allowed.

Related Conditions & MeSH terms

• Cancer
• Chondrosarcoma
• Neoplasms
• Sarcoma
• Sarcoma,Soft Tissue
• Solid Tumor, Adult

Intervention

Biological:
• AdAPT-001
Oncolytic virus administered by intratumoral injection

Drug:
• Checkpoint Inhibitor, Immune
Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio
United States	Mary Crowley Cancer Research	Dallas	Texas
United States	City of Hope	Duarte	California
United States	MD Anderson Cancer Center	Houston	Texas
United States	California Cancer Associates for Research and Excellence, cCARE	San Marcos	California
United States	Providence Saint John's Health Center	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
EpicentRx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Anti-tumor activity by iRECIST	ORR and best overall response rates per Immune Response Evaluation Criteria in Solid Tumors (iRECIST)	6 months
Other	Biodistribution	This outcome will measure TGFß trap concentrations in the serum and, in patients who consent to tissue collections, test for TGFß trap expression in the treated tumors.	6 months
Primary	Dose Limiting Toxicities (DLT)	All subjects in PART 1 will be assessed for the development of dose-limiting toxicity (DLT) during treatment with AdAPT-001. The DLT assessment period is defined as: Day of Injection through 28 days post injection (Safety Follow Up). A DLT will be defined as any Grade 3 or higher adverse event, as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.	28 days
Primary	Maximum tolerated dose	In PART 1, A MTD is determined if any cohort experiences 2 subjects with DLT's.	28 days
Primary	Safety of a multiple dose regimen of AdAPT-001	The safety data will include adverse events, serious adverse events, performance status, clinical laboratory tests, vital signs and physical examination results.	6 months
Primary	Anti-tumor activity of the two-arm dose regimens of AdAPT-001 in Phase 2	To evaluate the efficacy of the two-arm dose regimens of AdAPT-001 in subjects with advanced solid tumors that have progressed after treatment with standard therapies or for which there are no appropriate therapies available as measured by durable (=4 months) stable disease per Response Evaluation Criteria in Solid Tumors (RECIST).	6 months
Secondary	Anti-tumor activity of AdAPT-001	In PART 2 and PART 3, overall response rate (ORR) and best overall response rates per response evaluation criteria outlined in Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), as well as progression-free survival (PFS), and duration of response will be assessed.	6 months
Secondary	Objective response rate	Preliminarily to assess anti-tumor activity of AdAPT-001 by objective response rates (ORR) and best overall response rates per response evaluation criteria outlined in RECIST guideline (Version 1.1),	6 months